While the Underweight rating suggests a cautious view on Kodiak Sciences, the increase in price target from $2 to $3 indicates a slight improvement in Barclays' outlook for the company. This could lead to mixed reactions in the short term, as the market weighs the negative rating against the positive adjustment in price target.